Lilly Just Paid $2.4 Billion for a Circle. Here's Why.

Orna wants to do the engine swap while the car is still in your driveway. Using circular RNA packaged in tiny fat bubbles called lipid nanoparticles (LNPs), their platform delivers genetic instructions directly into a patient's immune cells in vivo (inside the body). No extraction. No factory. Your immune system gets reprogrammed on the spot.

Their lead program, ORN-252, is a clinical trial-ready therapy that targets CD19, a protein found on certain immune cells called B cells. The initial focus: B-cell-driven autoimmune diseases, conditions where the immune system attacks the body's own tissues. If the approach works in autoimmune disease, the same platform could extend to oncology and beyond.

Lilly's Shopping Spree Has a Theme

Orna isn't an impulse buy. It's part of a very deliberate pattern.

In April 2026, Lilly agreed to acquire Kelonia Therapeutics for up to $7.0 billion, another in vivo CAR-T and gene-delivery company. The company also struck a strategic alliance with Repertoire Immune Medicines worth up to $1.84 billion in milestones, focused on "tolerizing" therapies for autoimmune disease.

Add it up and the picture is clear: Lilly is assembling a genetic medicine arsenal focused on reprogramming the immune system from the inside. The company built its recent reputation (and its stock price) on obesity drugs like tirzepatide. Now it's placing massive bets that the next growth chapter comes from immunology and cell therapy.

Three major deals in a single year, all pointed in the same direction. That's not diversification; that's conviction.

Wall Street's Verdict: Excited, but Nervous

Analysts generally liked the strategic logic but also sounded a clear warning: the technology remains high risk and unvalidated in large-scale trials.

That tension captures the deal perfectly. Circular RNA is genuinely promising, but it's still early. Nobody has taken a circRNA therapy through a large clinical trial yet. The entire field is competing on platform potential and preclinical data, not approved products. Lilly is essentially buying a blueprint and betting it can build the house.

A Crowded Starting Line

Lilly isn't the only one who sees the opportunity. The circular RNA space has attracted serious money from multiple directions.

Laronde Therapeutics has raised roughly $490 million to develop its own circRNA platform focused on prolonged protein expression. Circio completed a NOK 250 million private placement in April 2026. RiboX Therapeutics reportedly became one of the first circRNA programs to receive FDA clearance for clinical trials in 2024. Smaller players like Sail Biomedicines, Torque Bio, and Chimera Therapeutics are also in the mix.

The sector is fragmented and early-stage, with companies competing mostly on delivery technology, durability of expression, and the quality of their partnerships. But big pharma money is flowing in fast, and Lilly's $2.4 billion bet raises the stakes for everyone.

The $2.4 Billion Question

Can you actually reprogram a person's immune system with a circular piece of RNA delivered in a fat bubble? In mice, Orna's earlier in situ CAR program showed complete tumor eradication. In humans, we don't know yet. ORN-252 is described as clinical trial-ready, which means the real test is coming soon.

If it works, Lilly will have bought a platform that could generate therapies across autoimmune disease, cancer, vaccines, and genetic disorders, all from a single underlying technology. That would make $2.4 billion look like a bargain.

If it doesn't, Lilly will have paid billions for a very expensive geometry lesson.

The circle is drawn. Now Lilly has to prove it's not just going around in circles.

A Nobel Laureate Thinks He Can Simulate an Entire Human Cell

David Baker's GenBio AI just unveiled a virtual cell that claims to simulate human biology from DNA to whole-cell behavior in one AI system. It's the boldest bet yet in computational biology, and the early results are turning heads.